Postepy Psychiatrii i Neurologii is a prominent academic journal dedicated to advancing the fields of psychiatry and neurology. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal has become an essential resource for researchers, clinicians, and students, fostering interdisciplinary communication and dialogue. With a record of publication extending from 2007 to 2024, it has carved a niche in important subfields, reflected in its category quartile rankings: Q3 in Clinical Psychology and Q4 in Neurology, Psychiatry, and Mental Health for 2023. Though it currently does not offer open access, the journal maintains a commitment to high-quality research dissemination. As a vital platform for sharing innovative findings and clinical practices, Postepy Psychiatrii i Neurologii contributes significantly to the global discourse on mental health and neurological disorders, making it an indispensable tool for academics and practitioners alike.

The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

General Psychiatry is a leading open-access journal published by BMJ PUBLISHING GROUP, dedicated to advancing the field of psychiatry and mental health. With an impressive impact factor and ranked in the Q1 category across various related disciplines—including Psychiatry and Mental Health, as well as Clinical Neurology—this journal offers a vital platform for researchers and practitioners in the field to disseminate high-quality studies and insights. The journal has been open access since 2018, ensuring that the latest research is freely available to a global audience, thus fostering greater collaboration and innovation. With a focus on significant developments and emerging trends, General Psychiatry serves as an essential resource for professionals keen on improving mental health practices and understanding neurological aspects of mental disorders. The journal is based in the United Kingdom, reflecting a commitment to global health discussions and initiatives in psychiatry.